Furthermore, recent reports showed that a large proportion of cancers with MSI are sensitive to anti-programmed cell death protein 1 (PD-1) immune checkpoint inhibitors, regardless of cancer site or origin [31]. This evidence concerns the gene PDCD1 and cancer.